{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T02:11:03Z","timestamp":1654567863717},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In a phase III trial involving more than 1,200 patients with follicular lymphoma, obinutuzumab plus chemotherapy reduced the risk of disease progression, relapse, or death by 34% compared with rituximab plus chemotherapy. However, patients receiving obinutuzumab experienced more serious side effects than those receiving rituximab.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2017-146","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T00:25:22Z","timestamp":1508891122000},"page":"OF3-OF3","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Obinutuzumab Effective in Follicular Lymphoma, but at a Cost"],"prefix":"10.1158","volume":"7","member":"1086","published-online":{"date-parts":[[2017,12,4]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/7\/12\/OF3\/40409\/Obinutuzumab-Effective-in-Follicular-Lymphoma-but","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/7\/12\/OF3\/40409\/Obinutuzumab-Effective-in-Follicular-Lymphoma-but","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T01:54:30Z","timestamp":1654566870000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/7\/12\/OF3\/40409\/Obinutuzumab-Effective-in-Follicular-Lymphoma-but"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":0,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12,4]]},"published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2017-146","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}